A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The current proposed study aims to bring answers following issues: the antiviral efficacy and
safety profiles in Korean Chronic Hepatitis B (CHB) patients who are mostly infected with
solely genotype C HBV, a proper duration of Pegasys® therapy post-treatment durability or
accumulation of HBeAg seroconversion/HBsAg loss, preventable effect on long-term disease
progression to liver cirrhosis and liver cancer. In addition, this study aims to collect more
data on the efficacy and safety in a real-life clinical setting of Pegasys® therapy in
patients with CHB.